Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...9899100101102103104105106107108...123124»
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Lenvatinib for thymic carcinomas. (Pubmed Central) -  Jul 21, 2020   
    Clinical trial identification: NCT03951597. No abstract available
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open, Metastases:  Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) (clinicaltrials.gov) -  Jul 14, 2020   
    P1,  N=15, Recruiting, 
    Active, not recruiting --> Recruiting Suspended --> Recruiting
  • ||||||||||  Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment closed, Trial primary completion date, Metastases:  LTHAIC: HAIC Plus Lenvatinib and Toripalimab for Advanced HCC (clinicaltrials.gov) -  Jul 13, 2020   
    P2,  N=35, Active, not recruiting, 
    Suspended --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2020 --> Sep 2020